Bavarian Nordic A/S (ETR:BV3)

Market Cap	2.02B +21.3%
Revenue (ttm)	796.79M -4.4%
Net Income	157.02M -11.2%
EPS	1.98 -10.7%
Shares Out	n/a
PE Ratio	12.85
Forward PE	18.42
Dividend	n/a
Ex-Dividend Date	n/a

Volume	440
Average Volume	537
Open	26.62
Previous Close	26.42
Day's Range	26.04 - 26.62
52-Week Range	23.18 - 32.75
Beta	n/a
RSI	54.95
Earnings Date	May 13, 2026

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV, that is in phase 2 trial for the treatment of encephalitis viruses...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1992
• Employees: 1,861
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: BV3

Financial Performance

In 2025, Bavarian Nordic's revenue was 6.24 billion, an increase of 9.23% compared to the previous year's 5.72 billion. Earnings were 1.38 billion, an increase of 39.21%.

Financial numbers in DKK